Clinical trials: Diabetic Retinopathy, completed
Diabetic Retinopathy
Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation
This exploratory study will compare the effects of ranibizumab treatment with conventional macular laser therapy for patients with diabetic macular oedema.
- Trial name
- LUCIDATE (NCT01223612)
- Testing
- Ranibizumab, Modified ETDRS laser
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Microvascular Complications, Diabetic Retinopathy
The Effect of the Glycemic Variability on Macular Retinal Microcirculation and Cognitive Functions in Patient With Type 1 Diabetes
Revadiab is case-control study aimed to demonstrate that retinal capillary density is altered in patients with type 1 diabetes with glycemic variability compared to those with comparable glycemic control without glycemic…
- Conditions
- Microvascular Complications, Diabetic Retinopathy, Diabetes, Microangiopathy
- Trial name
- REVADIAB (NCT03821753)
- Testing
- Case, Control
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetic Macular Edema
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
- Trial name
- NCT00536692
- Testing
- mecamylamine
- Where
- 3 sites in United States
- Sponsor
- CoMentis
Retinopathy, Diabetic
Assessment of Color Vision in Diabetic Patients
Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema
- Trial name
- NCT03345667
- Testing
- lucentis
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Instituto de Olhos de Goiania
Diabetic Macular Edema
Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema
Diabetics retinopathy remains the major threat to sight in the working age population in the developed world. Furthermore, it is increasing as a major cause of blindness in other parts of the world, especially developing…
- Trial name
- NEVANAC (NCT00780780)
- Testing
- Triamcinolone + Nepafenac, triamcinolone intravitreal injection
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Federal University of São Paulo
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
Given the high number of people with DMO and PDR, the need for patients to be seen at short follow-up intervals, the need for frequent treatments and the requirement for long-term follow-up, there is a very large workload in…
- Trial name
- EMERALD (NCT03490318)
- Where
- 13 sites in United Kingdom
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Belfast Health and Social Care Trust
Diabetic Retinopathy, Diabetic Macular Edema
Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema
This study will evaluate the clinical efficacy of intra-vitreal injections of Ranibizumab (Lucentis) in the treatment of Diabetic Macular Edema as compared to grid/focal laser.
- Trial name
- NCT00387582
- Testing
- Ranibizumab (Lucentis), Argon Laser
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Rocky Mountain Retina Consultants
Anti- VGF Inhibitor, Diabetic Macular Edema
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
This study will asses sthe safety of pegaptanib sodium in patients with diabetic macular edema. The hypothesis is that pegaptanib is safe and efficacious in patients with diabetic macular edema.
- Conditions
- Anti- VGF Inhibitor, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT01189461
- Testing
- pegaptanib sodium
- Where
- 12 sites in Finland, Spain and 2 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Diabetic Retinopathy
Pattern Laser Versus Conventional Laser in Diabetic Retinopathy
Purpose: To evaluate the clinical efficiency, safety and painfulness of retinal laser photocoagulation employing a pattern scanning laser system Pascal given in a single-session versus conventional laser multiple-session…
- Trial name
- NCT03672656
- Testing
- lasercoagulation by Pascal system, conventional laser
- Volunteers
- 30 people
- Sponsor
- University Hospital Ostrava
Diabetic Macular Edema
Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema
Purpose: To compare the effects of macular photocoagulation with or without intravitreal bevacizumab (IVB) or triamcinolone (IVTA) for the treatment of diabetic macular edema (DME).
- Trial name
- IBeTA (NCT02310295)
- Testing
- Laser, Bevacizumab, Triamcinolone Acetonide
- Volunteers
- 45 people
- Sponsor
- University of Sao Paulo
Vein Occlusion, Macular Degeneration Choroidal Neovascularization
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
The goal of this clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain.
- Conditions
- Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07090044
- Testing
- Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Retina Research Institute, LLC
Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment
Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy
We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular tissue and whole body, intravitreal injection of a low concentration of bevacizumab and conducting vitrectomy shortly after the injection is…
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Traction Retinal Detachment, Vitreous Hemorrhage
- Trial name
- NCT01854593
- Testing
- Bevacizumab, Vitrectomy
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Nihon University
Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration
Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in…
- Conditions
- Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- LUMINOUS (NCT01318941)
- Testing
- Ranibizumab
- Where
- 463 sites in Argentina, Australia and 41 more
- Volunteers
- 30,490 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Macular Degeneration, Diabetic Macular Edema
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
- Trial name
- NCT01473251
- Testing
- Avastin, Lucentis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vitreo-Retinal Associates, Michigan
Retinal Neovascularization
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
The purpose of this study is to determine the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.
- Trial name
- NCT01769183
- Testing
- Squalamine Lactate ophthalmic solution 0.2%
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Elman Retina Group
Diabetic Macular Edema, Diabetic Retinopathy
Imaging Parameters and DME Treatment Response
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients. While anti-VEGF treatments and to a lesser extent corticosteroid and macular photocoagulation have improved outcomes in patients with DME…
- Trial name
- NCT02637245
- Testing
- No intervention
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Type 2 Diabetic Retinopathy
The Effect Evaluation of Continuous Nursing Intervention in Patients With Type 2 Diabetic Retinopathy
Objective: To evaluate the application effect of continuous nursing intervention in type 2 diabetic retinopathy (DR), and to explore its clinical application value.
- Trial name
- NCT05716308
- Testing
- A continuous nursing intervention group was established.
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Proliferative Diabetic Retinopathy
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR).
- Trial name
- CONDOR (NCT04278417)
- Testing
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 689 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Automated Diagnostic Test for Diabetic Retinopathy in Brazilian Mass Screening
In Brazil 10% of the adult population has diabetes. Of these, 39.0% are undiagnosed, at risk for developing complications such as diabetic retinopathy (DR).
- Trial name
- NCT02927561
- Testing
- Diabetic Retinopathy screening
- Where
- Brazil
- Volunteers
- 220 people
- Sponsor
- Retina Clinic, Sao Paulo, Brazil